Skip to main content
ConductScienceScienceDex
NIH funding notice RFA-DA-23-045

HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed)

Closed on February 2, 2023.

Posted
July 7, 2022
Close date
February 2, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

1 competing award (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $640,347 in first-year total cost, median $640,347.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 GXM-M (A1)]1

Most frequent institutions

  1. UNIVERSITY OF CALIFORNIA, SAN DIEGO1
Competing awards under RFA-DA-23-045 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Development and validation of a novel point-of-care technology for rapid non-targeted identification of emerging opioid and other drug threats1UG1DA059406-01HALL, DREW ALEXANDERWERB, DANIEL MUNIVERSITY OF CALIFORNIA, SAN DIEGO, CA$640,347ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

Start your CVHow the NIH biosketch works
RFA-DA-23-045: HEAL Initiative: Rapidly Assessing the Public Health Impact of Emerging Opioid Threats (UG1 - Clinical Trial Not Allowed) | ScienceDex | ConductScience